KR101719966B1 - 종양 줄기세포에서 eph 수용체의 발현 - Google Patents

종양 줄기세포에서 eph 수용체의 발현 Download PDF

Info

Publication number
KR101719966B1
KR101719966B1 KR1020167002577A KR20167002577A KR101719966B1 KR 101719966 B1 KR101719966 B1 KR 101719966B1 KR 1020167002577 A KR1020167002577 A KR 1020167002577A KR 20167002577 A KR20167002577 A KR 20167002577A KR 101719966 B1 KR101719966 B1 KR 101719966B1
Authority
KR
South Korea
Prior art keywords
epha2
gbm
cells
pharmaceutical composition
precursor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167002577A
Other languages
English (en)
Korean (ko)
Other versions
KR20160027106A (ko
Inventor
안젤로 루이지 베스코비
엘레나 빈다
Original Assignee
스템젠 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스템젠 에스.피.에이. filed Critical 스템젠 에스.피.에이.
Publication of KR20160027106A publication Critical patent/KR20160027106A/ko
Application granted granted Critical
Publication of KR101719966B1 publication Critical patent/KR101719966B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020167002577A 2010-10-01 2011-09-30 종양 줄기세포에서 eph 수용체의 발현 Active KR101719966B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10185930A EP2446895A1 (en) 2010-10-01 2010-10-01 EPH receptor expression in tumor stem cells
EP10185930.4 2010-10-01
PCT/EP2011/067114 WO2012042021A1 (en) 2010-10-01 2011-09-30 Eph receptor expression in tumor stem cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137011310A Division KR20130095286A (ko) 2010-10-01 2011-09-30 종양 줄기세포에서 eph 수용체의 발현

Publications (2)

Publication Number Publication Date
KR20160027106A KR20160027106A (ko) 2016-03-09
KR101719966B1 true KR101719966B1 (ko) 2017-03-24

Family

ID=43856109

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167002577A Active KR101719966B1 (ko) 2010-10-01 2011-09-30 종양 줄기세포에서 eph 수용체의 발현
KR1020137011310A Ceased KR20130095286A (ko) 2010-10-01 2011-09-30 종양 줄기세포에서 eph 수용체의 발현

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137011310A Ceased KR20130095286A (ko) 2010-10-01 2011-09-30 종양 줄기세포에서 eph 수용체의 발현

Country Status (11)

Country Link
US (1) US9078857B2 (https=)
EP (2) EP2446895A1 (https=)
JP (4) JP2013540117A (https=)
KR (2) KR101719966B1 (https=)
AU (1) AU2011310109B2 (https=)
CA (1) CA2813101C (https=)
DK (1) DK2621513T3 (https=)
ES (1) ES2616444T3 (https=)
NZ (1) NZ609594A (https=)
PL (1) PL2621513T3 (https=)
WO (1) WO2012042021A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118547A1 (en) 2010-12-08 2012-09-07 Stem Centrx, Inc. Novel modulators and methods of use
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
EP2733206A1 (en) * 2012-11-19 2014-05-21 Naroa LLC Method for the isolation for mammalian stem cells using EphA2 and uses thereof
CN105828841A (zh) 2013-11-04 2016-08-03 辉瑞大药厂 抗-efna4抗体-药物缀合物
US9777070B2 (en) 2014-04-30 2017-10-03 Pfizer Inc Anti-PTK7 antibody-drug conjugates
JP6921755B2 (ja) 2014-12-10 2021-08-18 ハイパーステム ソシエテ アノニム 脳腫瘍幹細胞の成長、遊走および浸潤性を低下させ脳腫瘍患者の生存率を改善する方法および組成物
CN107851031B (zh) 2015-05-08 2021-05-28 佛罗乔有限责任公司 数据发现节点
IL289849B2 (en) 2015-11-10 2024-01-01 Nat Inst Biotechnology Negev Ltd Means and methods for reducing tumorigenicity of cancer stem cells
JP7680047B2 (ja) * 2020-03-31 2025-05-20 慶應義塾 ゲノム編集多能性幹細胞を用いた治療薬
WO2026022122A1 (en) * 2024-07-23 2026-01-29 Eos Research Sa Checkpoint inhibitors in the treatment of glioblastoma multiforme

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004281834A1 (en) * 2003-10-15 2005-04-28 Cerus Corporation Listeria-based EphA2 vaccines
EP1778726A4 (en) * 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
US8343461B2 (en) * 2006-03-08 2013-01-01 Wake Forest University Health Sciences Molecular signature of cancer
HRP20170407T1 (hr) * 2007-08-30 2017-05-05 Daiichi Sankyo Company, Limited Anti-epha2 anitijelo

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Mol. Cancer Res. Vol 3, pages 541-551 (2005)*
Oncology Reports, Vol. 19, pages 151-156 (2008)*

Also Published As

Publication number Publication date
CA2813101C (en) 2018-10-30
WO2012042021A1 (en) 2012-04-05
KR20130095286A (ko) 2013-08-27
JP2013540117A (ja) 2013-10-31
EP2621513A1 (en) 2013-08-07
US20120083454A1 (en) 2012-04-05
JP2016094391A (ja) 2016-05-26
AU2011310109B2 (en) 2014-11-20
EP2446895A1 (en) 2012-05-02
JP2018048151A (ja) 2018-03-29
EP2621513B1 (en) 2016-12-28
ES2616444T3 (es) 2017-06-13
US9078857B2 (en) 2015-07-14
CA2813101A1 (en) 2012-04-05
KR20160027106A (ko) 2016-03-09
AU2011310109A1 (en) 2013-05-02
JP2020037579A (ja) 2020-03-12
DK2621513T3 (en) 2017-03-06
PL2621513T3 (pl) 2017-06-30
JP6523910B2 (ja) 2019-06-05
JP6618968B2 (ja) 2019-12-11
NZ609594A (en) 2015-01-30

Similar Documents

Publication Publication Date Title
KR101719966B1 (ko) 종양 줄기세포에서 eph 수용체의 발현
Willis et al. Chronic inflammatory pain and the neurovascular unit: a central role for glia in maintaining BBB integrity?
JP5891068B2 (ja) Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制
SG195557A1 (en) Modulation of axon degeneration
AU2004275798A1 (en) VEGE-Cor VEGE-D materials and methods for stimulation of neural stem cells
US9730935B2 (en) Targeting a non-canonical notch signaling pathway for cancer treatment
US20090163406A1 (en) Compositions and methods for diagnosing and treating brain cancer and identifying neural stem cells
Fang et al. Enhanced cell growth and tumorigenicity of rat glioma cells by stable expression of human CD133 through multiple molecular actions
KR20200028982A (ko) 시냅스 기능을 증진시키기 위한 hdac2-sp3 복합체 표적화
Tokarew The Role of Norrie Disease Pseudoglioma (Ndp) in Cerebellar Development/Tumorigenesis and Its Relationship with the Sonic Hedgehog Pathway
Al-Zahrani The Role of the Ste20-like Kinase in Embryonic Development and Neu-induced Mammary Tumorigenesis
Ludwig Mechanisms of KCC2 upregulation during development
Wang Jr The Role of ING5 in Maintaining Stemness of Brain Tumor Initiating Cells
HK40077266B (zh) 抗癌剂
Lee Molecular Action of a Potential Tumor Suppression in Mammary Carcinogenesis
Fiaschetti Targeting MYC and MYC target genes as therapeutic strategies in childhood medulloblastoma
Soskis A Chemical-Genetic Study of EphB Receptor Tyrosine Kinase Signaling in the Developing Nervous System
Huber The Molecular Role of Non-canonical Notch Signaling Via Deltex-1 in High Grade Glioma
Minas ETS family of transcription factors as a therapeutic target in cancer
Comejo et al. Crosstalk between Notch and AKT signaling differentially regulates megakaryocyte development from hematopoietic stem and committed progenitor cells
Liang Targeting the Notch-1/IGF-1R/Akt Axis in at Orthotopic Model of Advanced Non-Small Cell Lung Cancer
Kabos et al. Ritsuko Iwanaga1, Chu-An Wang2, Douglas S Micalizzi2, 3, J Chuck Harrell4, Paul Jedlicka5, Carol A Sartorius5
AU2015202365A1 (en) Modulation of axon degeneration

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20200312

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20210312

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20220311

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10